N,N-bis(2-iodoethyl)-4-nitroaniline | 122567-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-bis(2-iodoethyl)-4-nitroaniline
• CAS: 122567-48-0
• 化学式: C₁₀H₁₂I₂N₂O₂
• 分子量: 446.026
• InChiKey: HLDANTMIUPBSGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 、 N,N-bis(2-iodoethyl)-4-nitroaniline 在 copper(l) iodide 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 5'-methoxy-1-(4-nitrophenyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES HÉTÉROCYCLIQUES DES RÉCEPTEURS CGRP

  摘要：

  本发明涉及杂环化合物，其为CGRP受体拮抗剂，可能在治疗或预防涉及CGRP的疾病（如偏头痛）方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。

  公开号：

  WO2016022644A1
• 作为产物：
  描述：

  N,N-bis<2-<(methylsulfonyl)oxy>ethyl>-4-nitroaniline 在 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 N,N-bis(2-iodoethyl)-4-nitroaniline
  参考文献：
  名称：

  [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES HÉTÉROCYCLIQUES DES RÉCEPTEURS CGRP

  摘要：

  本发明涉及杂环化合物，其为CGRP受体拮抗剂，可能在治疗或预防涉及CGRP的疾病（如偏头痛）方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。

  公开号：

  WO2016022644A1

文献信息

• Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines
  作者：Brian D. Palmer、William R. Wilson、Susan M. Pullen、William A. Denny

  DOI：10.1021/jm00163a019

  日期：1990.1

  A series of aniline mustards with a wide range of electron-donating and -withdrawing substituents in the 3- and 4-positions has been synthesized and evaluated for cytotoxicity in cell culture to examine the potential of using nitro group deactivated nitrogen mustards for the design of novel hypoxia-selective anticancer drugs (Denny, W. A.; Wilson, W. R. J. Med. Chem. 1986, 29, 879). Hydrolytic half-lives in tissue culture media, determined by bioassay against a cell line (UV4) defective in the repair of DNA interstrand cross-links showed the expected dependence on the Hammett electronic parameter, sigma, varying from 0.13 h for the 4-amino analogue to greater than 100 h for analogues with strongly electron-withdrawing substituents. Cytotoxic potencies in aerobic UV4 cultures showed a similar dependence on sigma. This dependence predicted that the 4-nitroaniline mustard would be 7200-fold less potent than its potential six-electron reduction product, the 4-amino compound, in growth inhibition assays using a 1-h drug exposure. The measured differential was much lower (225-fold) because of the instability of the latter compound, but a differential of 17,500-fold was observed in the initial rate of killing by using a clonogenic assay. The potential for formation of reactive mustards by reduction to the amine or hydroxylamine was demonstrated by the 4-nitroso compound, which had an aerobic toxicity similar to that of the amine. Although these features confirmed the original rationale, the 3-nitro- and 4-nitroaniline mustards had only minimal hypoxic selectivity against UV cells. Toxicity to hypoxic cells appears to be limited by the low reduction potentials of these compounds and consequent lack of enzymatic nitroreduction. However, this study has demonstrated that nitro groups can be used to latentiate aromatic nitrogen mustards and indicates that examples with higher reduction potentials could provide useful hypoxia-selective therapeutic agents.
• [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DES RÉCEPTEURS CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022644A1

  公开（公告）日：2016-02-11

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其为CGRP受体拮抗剂，可能在治疗或预防涉及CGRP的疾病（如偏头痛）方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。